A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma

Sergio Fernández-Pello, Fabian Hofmann, Rana Tahbaz, Lorenzo Marconi, Thomas B Lam, Laurence Albiges, Karim Bensalah, Steven E. Canfield, Saeed Dabestani, Rachel H. Giles, Milan Hora, Markus A. Kuczyk, Axel S. Merseburger, Thomas Powles, Michael Staehler, Alessandro Volpe, Börje Ljungberg, Axel Bex

Research output: Contribution to journalArticle

35 Citations (Scopus)
7 Downloads (Pure)

Abstract

Context
While vascular endothelial growth factor-targeted therapy and mammalian target of rapamycin inhibition are effective strategies in treating clear cell renal cell carcinoma (ccRCC), the most effective therapeutic approach for patients with non-clear cell RCC (non-ccRCC) is unknown.

Objective
To systematically review relevant literature comparing the oncological outcomes and adverse events of different systemic therapies for patients with metastatic non-ccRCC.

Evidence acquisition
Relevant databases including MEDLINE, Embase, and the Cochrane Library were searched up to March 24, 2016. Only comparative studies were included. Risk of bias and confounding assessments were performed. A meta-analysis was planned for and only performed if methodologically appropriate; otherwise, a narrative synthesis was undertaken.

Evidence synthesis
The literature search identified 812 potential titles and abstracts. Five randomized controlled trials, recruiting a total of 365 patients, were included. Three studies compared sunitinib against everolimus, one of which reported the results for non-ccRCC as a subgroup rather than as an entire randomized cohort. Individually, the studies showed a trend towards favoring sunitinib in terms of overall survival and progression-free survival (PFS; Everolimus versus Sunitinib in Patients with Metastatic Non-clear Cell Renal Cell Carcinoma hazard ratio [HR]: 1.41, 80% confidence interval [CI] 1.03–1.92 and 1.41, 95% CI: 0.88–2.27, Evaluation in Metastatic Non-clear Cell Renal Cell Carcinoma HR: 1.16, 95% CI: 0.67–2.01, Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients with Metastatic Renal Cell Carcinoma HR: 1.5, 95% CI: 0.9–2.8), but this trend did not reach statistical significance in any study. Meta-analysis was performed on two studies which solely recruited patients with non-ccRCC reporting on PFS, the results of which were inconclusive (HR: 1.30, 95% CI: 0.91–1.86). Sunitinib was associated with more Grade 3–4 adverse events than everolimus, although this was not statistically significant.

Conclusions
This systematic review and meta-analysis represent a robust summary of the evidence base for systemic treatment of metastatic non-ccRCC. The results show a trend towards favoring vascular endothelial growth factor-targeted therapy for PFS and overall survival compared with mammalian target of rapamycin inhibitors, although statistical significance was not reached. The relative benefits and harms of these treatments remain uncertain. Further research, either in the form of an individual patient data meta-analysis involving all relevant trials, or a randomized controlled trial with sufficient power to detect potential differences between treatments, is needed.
Original languageEnglish
Pages (from-to)426–436
Number of pages11
JournalEuropean Urology
Volume71
Issue number3
Early online date8 Dec 2016
DOIs
Publication statusPublished - 1 Mar 2017

Fingerprint

Renal Cell Carcinoma
Meta-Analysis
Confidence Intervals
Sirolimus
Therapeutics
Vascular Endothelial Growth Factor A
Randomized Controlled Trials
Survival
MEDLINE
Libraries
Disease-Free Survival
sunitinib
Databases
Safety
Everolimus
Research

Keywords

  • non-clear cell renal carcinoma
  • papillary
  • chromophobe
  • sunitinib
  • everolimus
  • systematic review

Cite this

A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma. / Fernández-Pello, Sergio ; Hofmann, Fabian; Tahbaz, Rana ; Marconi, Lorenzo; Lam, Thomas B; Albiges, Laurence; Bensalah, Karim ; Canfield, Steven E.; Dabestani, Saeed; Giles, Rachel H. ; Hora, Milan ; Kuczyk, Markus A. ; Merseburger, Axel S. ; Powles, Thomas; Staehler, Michael; Volpe, Alessandro ; Ljungberg, Börje; Bex, Axel.

In: European Urology, Vol. 71, No. 3, 01.03.2017, p. 426–436.

Research output: Contribution to journalArticle

Fernández-Pello, S, Hofmann, F, Tahbaz, R, Marconi, L, Lam, TB, Albiges, L, Bensalah, K, Canfield, SE, Dabestani, S, Giles, RH, Hora, M, Kuczyk, MA, Merseburger, AS, Powles, T, Staehler, M, Volpe, A, Ljungberg, B & Bex, A 2017, 'A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma', European Urology, vol. 71, no. 3, pp. 426–436. https://doi.org/10.1016/j.eururo.2016.11.020
Fernández-Pello, Sergio ; Hofmann, Fabian ; Tahbaz, Rana ; Marconi, Lorenzo ; Lam, Thomas B ; Albiges, Laurence ; Bensalah, Karim ; Canfield, Steven E. ; Dabestani, Saeed ; Giles, Rachel H. ; Hora, Milan ; Kuczyk, Markus A. ; Merseburger, Axel S. ; Powles, Thomas ; Staehler, Michael ; Volpe, Alessandro ; Ljungberg, Börje ; Bex, Axel. / A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma. In: European Urology. 2017 ; Vol. 71, No. 3. pp. 426–436.
@article{1a7e73d4907e4e9fbe1c8410909cd53e,
title = "A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma",
abstract = "ContextWhile vascular endothelial growth factor-targeted therapy and mammalian target of rapamycin inhibition are effective strategies in treating clear cell renal cell carcinoma (ccRCC), the most effective therapeutic approach for patients with non-clear cell RCC (non-ccRCC) is unknown.ObjectiveTo systematically review relevant literature comparing the oncological outcomes and adverse events of different systemic therapies for patients with metastatic non-ccRCC.Evidence acquisitionRelevant databases including MEDLINE, Embase, and the Cochrane Library were searched up to March 24, 2016. Only comparative studies were included. Risk of bias and confounding assessments were performed. A meta-analysis was planned for and only performed if methodologically appropriate; otherwise, a narrative synthesis was undertaken.Evidence synthesisThe literature search identified 812 potential titles and abstracts. Five randomized controlled trials, recruiting a total of 365 patients, were included. Three studies compared sunitinib against everolimus, one of which reported the results for non-ccRCC as a subgroup rather than as an entire randomized cohort. Individually, the studies showed a trend towards favoring sunitinib in terms of overall survival and progression-free survival (PFS; Everolimus versus Sunitinib in Patients with Metastatic Non-clear Cell Renal Cell Carcinoma hazard ratio [HR]: 1.41, 80{\%} confidence interval [CI] 1.03–1.92 and 1.41, 95{\%} CI: 0.88–2.27, Evaluation in Metastatic Non-clear Cell Renal Cell Carcinoma HR: 1.16, 95{\%} CI: 0.67–2.01, Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients with Metastatic Renal Cell Carcinoma HR: 1.5, 95{\%} CI: 0.9–2.8), but this trend did not reach statistical significance in any study. Meta-analysis was performed on two studies which solely recruited patients with non-ccRCC reporting on PFS, the results of which were inconclusive (HR: 1.30, 95{\%} CI: 0.91–1.86). Sunitinib was associated with more Grade 3–4 adverse events than everolimus, although this was not statistically significant.ConclusionsThis systematic review and meta-analysis represent a robust summary of the evidence base for systemic treatment of metastatic non-ccRCC. The results show a trend towards favoring vascular endothelial growth factor-targeted therapy for PFS and overall survival compared with mammalian target of rapamycin inhibitors, although statistical significance was not reached. The relative benefits and harms of these treatments remain uncertain. Further research, either in the form of an individual patient data meta-analysis involving all relevant trials, or a randomized controlled trial with sufficient power to detect potential differences between treatments, is needed.",
keywords = "non-clear cell renal carcinoma, papillary, chromophobe, sunitinib, everolimus, systematic review",
author = "Sergio Fern{\'a}ndez-Pello and Fabian Hofmann and Rana Tahbaz and Lorenzo Marconi and Lam, {Thomas B} and Laurence Albiges and Karim Bensalah and Canfield, {Steven E.} and Saeed Dabestani and Giles, {Rachel H.} and Milan Hora and Kuczyk, {Markus A.} and Merseburger, {Axel S.} and Thomas Powles and Michael Staehler and Alessandro Volpe and B{\"o}rje Ljungberg and Axel Bex",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.eururo.2016.11.020",
language = "English",
volume = "71",
pages = "426–436",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma

AU - Fernández-Pello, Sergio

AU - Hofmann, Fabian

AU - Tahbaz, Rana

AU - Marconi, Lorenzo

AU - Lam, Thomas B

AU - Albiges, Laurence

AU - Bensalah, Karim

AU - Canfield, Steven E.

AU - Dabestani, Saeed

AU - Giles, Rachel H.

AU - Hora, Milan

AU - Kuczyk, Markus A.

AU - Merseburger, Axel S.

AU - Powles, Thomas

AU - Staehler, Michael

AU - Volpe, Alessandro

AU - Ljungberg, Börje

AU - Bex, Axel

PY - 2017/3/1

Y1 - 2017/3/1

N2 - ContextWhile vascular endothelial growth factor-targeted therapy and mammalian target of rapamycin inhibition are effective strategies in treating clear cell renal cell carcinoma (ccRCC), the most effective therapeutic approach for patients with non-clear cell RCC (non-ccRCC) is unknown.ObjectiveTo systematically review relevant literature comparing the oncological outcomes and adverse events of different systemic therapies for patients with metastatic non-ccRCC.Evidence acquisitionRelevant databases including MEDLINE, Embase, and the Cochrane Library were searched up to March 24, 2016. Only comparative studies were included. Risk of bias and confounding assessments were performed. A meta-analysis was planned for and only performed if methodologically appropriate; otherwise, a narrative synthesis was undertaken.Evidence synthesisThe literature search identified 812 potential titles and abstracts. Five randomized controlled trials, recruiting a total of 365 patients, were included. Three studies compared sunitinib against everolimus, one of which reported the results for non-ccRCC as a subgroup rather than as an entire randomized cohort. Individually, the studies showed a trend towards favoring sunitinib in terms of overall survival and progression-free survival (PFS; Everolimus versus Sunitinib in Patients with Metastatic Non-clear Cell Renal Cell Carcinoma hazard ratio [HR]: 1.41, 80% confidence interval [CI] 1.03–1.92 and 1.41, 95% CI: 0.88–2.27, Evaluation in Metastatic Non-clear Cell Renal Cell Carcinoma HR: 1.16, 95% CI: 0.67–2.01, Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients with Metastatic Renal Cell Carcinoma HR: 1.5, 95% CI: 0.9–2.8), but this trend did not reach statistical significance in any study. Meta-analysis was performed on two studies which solely recruited patients with non-ccRCC reporting on PFS, the results of which were inconclusive (HR: 1.30, 95% CI: 0.91–1.86). Sunitinib was associated with more Grade 3–4 adverse events than everolimus, although this was not statistically significant.ConclusionsThis systematic review and meta-analysis represent a robust summary of the evidence base for systemic treatment of metastatic non-ccRCC. The results show a trend towards favoring vascular endothelial growth factor-targeted therapy for PFS and overall survival compared with mammalian target of rapamycin inhibitors, although statistical significance was not reached. The relative benefits and harms of these treatments remain uncertain. Further research, either in the form of an individual patient data meta-analysis involving all relevant trials, or a randomized controlled trial with sufficient power to detect potential differences between treatments, is needed.

AB - ContextWhile vascular endothelial growth factor-targeted therapy and mammalian target of rapamycin inhibition are effective strategies in treating clear cell renal cell carcinoma (ccRCC), the most effective therapeutic approach for patients with non-clear cell RCC (non-ccRCC) is unknown.ObjectiveTo systematically review relevant literature comparing the oncological outcomes and adverse events of different systemic therapies for patients with metastatic non-ccRCC.Evidence acquisitionRelevant databases including MEDLINE, Embase, and the Cochrane Library were searched up to March 24, 2016. Only comparative studies were included. Risk of bias and confounding assessments were performed. A meta-analysis was planned for and only performed if methodologically appropriate; otherwise, a narrative synthesis was undertaken.Evidence synthesisThe literature search identified 812 potential titles and abstracts. Five randomized controlled trials, recruiting a total of 365 patients, were included. Three studies compared sunitinib against everolimus, one of which reported the results for non-ccRCC as a subgroup rather than as an entire randomized cohort. Individually, the studies showed a trend towards favoring sunitinib in terms of overall survival and progression-free survival (PFS; Everolimus versus Sunitinib in Patients with Metastatic Non-clear Cell Renal Cell Carcinoma hazard ratio [HR]: 1.41, 80% confidence interval [CI] 1.03–1.92 and 1.41, 95% CI: 0.88–2.27, Evaluation in Metastatic Non-clear Cell Renal Cell Carcinoma HR: 1.16, 95% CI: 0.67–2.01, Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients with Metastatic Renal Cell Carcinoma HR: 1.5, 95% CI: 0.9–2.8), but this trend did not reach statistical significance in any study. Meta-analysis was performed on two studies which solely recruited patients with non-ccRCC reporting on PFS, the results of which were inconclusive (HR: 1.30, 95% CI: 0.91–1.86). Sunitinib was associated with more Grade 3–4 adverse events than everolimus, although this was not statistically significant.ConclusionsThis systematic review and meta-analysis represent a robust summary of the evidence base for systemic treatment of metastatic non-ccRCC. The results show a trend towards favoring vascular endothelial growth factor-targeted therapy for PFS and overall survival compared with mammalian target of rapamycin inhibitors, although statistical significance was not reached. The relative benefits and harms of these treatments remain uncertain. Further research, either in the form of an individual patient data meta-analysis involving all relevant trials, or a randomized controlled trial with sufficient power to detect potential differences between treatments, is needed.

KW - non-clear cell renal carcinoma

KW - papillary

KW - chromophobe

KW - sunitinib

KW - everolimus

KW - systematic review

U2 - 10.1016/j.eururo.2016.11.020

DO - 10.1016/j.eururo.2016.11.020

M3 - Article

VL - 71

SP - 426

EP - 436

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 3

ER -